Alexander I. Spira, MD, PhD, FACP - Biomarkers at the Forefront: The Crucial Role of Testing Across Solid Tumor Types

episode

CME in Minutes: Education in Primary Care not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Booked out doesn't mean you're ready for an associate OD 23 min · 23 Sep 2026 · The Optometry Success Podcast

What the U.S. Can Learn from Canada's Safety Net + The Real Cost of Private Schools and Clubs 44 min · 23 Sep 2026 · The Prof G Pod with Scott Galloway

4AM ET 09/23/2026 Newscast 3 min · 23 Sep 2026 · Fox News Hourly Update

What happened to the giant bugs? 29 min · 23 Sep 2026 · Unexplainable

The original looksmaxxer who created our hell world 1h 9m · 23 Sep 2026 · Panic World

After Party 1h 0m · 23 Sep 2026 · The Lonely Island and Seth Meyers Podcast

Report any issue

Source

Recorded13 Dec 2024

Publisherc.answersincme.com ↗

Handlerec:10296257

Show notes

Please visit answersincme.com/SWT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the importance of biomarker testing in solid tumors. Upon completion of this activity, participants should be better able to: Recognize the impact of biomarker testing on patient outcomes across tumor types; Identify optimal strategies for implementing biomarker testing in clinical practice; and Outline patient-centered strategies to optimize outcomes following identification of actionable biomarkers/mutations.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in